SEC Comment Letter for Sol-Gel Technologies Ltd. (SLGL) (CIK 0001684693) (SLGL) — Jan 16, 2018
Sol-Gel Technologies Ltd. (SLGL) (CIK 0001684693)
Date: Jan. 16, 2018 · CIK: 0001684693 · Accession: 0000000000-18-001424
AI Filing Summary & Sentiment
File numbers found in text: 333-220234
Letter
Mail Stop 4546 January 12 , 201 8 Alon Seri -Levy Chief Executive Officer Sol-Gel Technologies Ltd. 7 Golda Meir St., Weizmann Science Park Ness Ziona, 7403648, Israel
Re: Sol-Gel Technologies Ltd. Amendment No. 3 to Registration Statement on Form F -1 Filed December 29, 2017 File No. 333-220234
Dear Mr. Seri -Levy :
We have reviewed your amended registration statement and have the following comment.
Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in y our response.
After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments.
Management’s Discussion and Analysis of Financial Condition and Results of Operat ions Collaboration Agreements, page 68
1. We note that on August 22, 2017, you received an in -process research and development product candidate from a related party together with an agreement with a third party for the development, manufacturing, and commer cialization of the product. Please expand your disclosure, here and elsewhere, to identify the product and collaborative partner. Additionally, disclose the material terms of the agreement, such as the duration, termination provisions, and each party’s r ights and obligations. File the agreement as an exhibit or provide an analysis supporting your determination that you are not required to file it pursuant to Item 601(b)(10) of Regulation S -K.
Alon Seri -Levy Sol-Gel Technologies Ltd. January 12 , 201 8 Page 2
You may contact Ibolya Ignat at (202) 551 -3636 or Angela Connell at (202) 551 -3426 if you have questions regarding comments on the financial statements and related matters. Please contact Jeffrey Gabor at (202) 551 -2544 or me at (202) 551 -3675 with any other questions.
Sincerely,
/s/ Suzanne Hayes
Show Raw Text
Mail Stop 4546 January 12 , 201 8 Alon Seri -Levy Chief Executive Officer Sol-Gel Technologies Ltd. 7 Golda Meir St., Weizmann Science Park Ness Ziona, 7403648, Israel Re: Sol-Gel Technologies Ltd. Amendment No. 3 to Registration Statement on Form F -1 Filed December 29, 2017 File No. 333-220234 Dear Mr. Seri -Levy : We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in y our response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Management’s Discussion and Analysis of Financial Condition and Results of Operat ions Collaboration Agreements, page 68 1. We note that on August 22, 2017, you received an in -process research and development product candidate from a related party together with an agreement with a third party for the development, manufacturing, and commer cialization of the product. Please expand your disclosure, here and elsewhere, to identify the product and collaborative partner. Additionally, disclose the material terms of the agreement, such as the duration, termination provisions, and each party’s r ights and obligations. File the agreement as an exhibit or provide an analysis supporting your determination that you are not required to file it pursuant to Item 601(b)(10) of Regulation S -K. Alon Seri -Levy Sol-Gel Technologies Ltd. January 12 , 201 8 Page 2 You may contact Ibolya Ignat at (202) 551 -3636 or Angela Connell at (202) 551 -3426 if you have questions regarding comments on the financial statements and related matters. Please contact Jeffrey Gabor at (202) 551 -2544 or me at (202) 551 -3675 with any other questions. Sincerely, /s/ Suzanne Hayes Suzanne Hayes Assistant Director Office of Healthcare & Insurance cc: Nathan Ajiashvili , Esq. Latham & Watkins LLP